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Abstract
Introduction: Adriamycin (ADR) is a potent chemotherapeutic agent, effective in the treatment of leukaemias, lymphomas and many
solid tumours. However, its clinical usage is often limited by cardiotoxicity, induced by oxygen radical damage of the membrane lipids.
Melatonin (MEL) is a well-known antioxidant. It has been shown that MEL can scavenge free radicals, both directly and indirectly, stimu-
lating the activity of antioxidative enzymes such as glutathione peroxidase (GSH-Px).
The aim of the study: The aim of the study was to examine the effect of MEL on serum and erythrocyte GSH-Px activity after ADR in
normal and pinealectomised rats.
Material and methods: Wistar rats were divided into the three groups: control animals (Intact), sham-operated (Sham-PX) and pinealec-
tomised (Px). Each of the groups was divided into four subgroups, injected with: 1 — saline, 2 — MEL, 3 — ADR and 4 —ADR + MEL.
ADR was administered 2 months after Px as a single dose (15 mg/kg, i.p.) 1 hour after the fourth melatonin injection. Melatonin (5 mg/kg,
i.p.) was administered for 4 days before and 2 days after ADR. After 6 days of treatment, the rats were killed by decapitation. Their blood
was collected for measurements.
Results: In serum GSH-Px activity decreased in all the groups after ADR. Pinealectomy decreased the activity of the enzyme in all the
groups of animals examined. In erythrocytes GSH-Px decreased after ADR in the Px-animals. The effect of pinealectomy on erythrocyte
GSH-Px activity was not as strongly expressed as serum GSH-Px activity. MEL did not change GSH-Px activity after ADR.
Conclusion: Melatonin, in pharmacological concentrations, did not influence the activity of GSH-Px, either in normal or in pinealectomi-
sed rats after ADR. A deficiency of endogenous melatonin production may inhibit GSH-Px activity.
(Pol J Endocrinol 2008; 59 (3): 200–206)
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Streszczenie
Wstęp: Adriamycyna (ADR, adriamycin) jest lekiem przeciwnowotworowym wykorzystywanym w leczeniu białaczek, chłoniaków czy
guzów litych. Jej efekt leczenia jest ograniczony ze względu na kardiotoksyczność indukowaną produkcją wolnych rodników, które
uszkadzają błony lipidowe.
Melatonina (MEL, melatonin) jest znanym antyoksydantem. Wykazano, że neutralizuje wolne rodniki w sposób bezpośredni lub pośredni,
stymulując enzymy antyoksydacyjne, w tym peroksydazę glutationu (GSH-Px, glutathione peroxidase).
Cel: Celem badania było zbadanie efektu melatoniny na aktywność GSH-Px w surowicy i erytrocytach po adriamycynie u zwierząt
nietkniętych i po usunięciu szyszynki.
Materiał i metody: Szczury samce szczepu Wistar podzielono na 3 grupy: grupę kontrolną (Intact — szczury nietknięte), po operacji
pozornej (Sham-Px) i po usunięciu szyszynki (Px). Każdą grupę podzielono na 4 podgrupy, w których podano injekcje: 1 — soli fizjolo-
gicznej, 2 — MEL, 3 — ADR i 4 — ADR + MEL. Adriamycynę podano 2 miesiące po Px w dawce jednorazowej (15 mg/kg mc.),
1 godzinę przed czwartym podaniem MEL. Melatoninę podawano przez 4 dni przed Px i przez 2 dni po ADR w dawce 5 mg/kg mc. Po
6 dniach leczenia zwierzęta zabito przez dekapitację, a krew zamrożono do momentu pomiarów.
Wyniki: Aktywność PSH-Px w surowicy obniżyła się po ADR we wszystkich badanych grupach. Po usunięciu szyszynki aktywność GSH-
Px w surowicy zmniejszyła się w grupach poddanych injekcjom. Aktywność GSH-Px w erytrocytach obniżyła się po ADR u zwierząt
poddanych Px. Zmiany aktywności GSH-Px w eytrocytach po usunięciu szyszynki były słabiej wyrażone w porównaniu z aktywnością
GSH-Px w surowicy. Melatonina nie zmieniła aktywności peroksydaz po ADR.
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Wnioski: Melatonina w dawce farmakologicznej nie wpłynęła na aktywność peroksydaz zarówno u zwierząt nietkniętych, jak i po usu-
nięciu szyszynki. Deficyt endogennej produkcji melatoniny może odgrywać rolę w hamowaniu aktywności peroksydaz.
(Endokrynol Pol 2008; 59 (3): 200–206)
Słowa kluczowe: peroksydaza glutationu, adriamycyna, melatonina, pinealektomia
Introduction
Antracycline antibiotics are widely used in the antine-
oplastic treatment of haemopoietic or solid tumours.
Cardiotoxicity is one of the most serious side effects of
these drugs [1]. Evidence collected for over 15 years in-
dicates that melatonin (MEL) influences the cardiova-
scular system [2–4].
Morishima et al. [5] (1999) reported that MEL pro-
tected against adriamycin (doxorubicin hydrochloride)-
induced cardiomyopathy, the pathogenesis of which
may involve free radical and lipid peroxidation. In that
study MEL was shown to affect zinc turnover, which
acts as an antioxidant. Similar results were obtained by
others; MEL was an effective antioxidant against adria-
mycin-induced cardiotoxicity of the myocardium [6–10].
The protective effect of MEL can partly depend on ca-
talase activity stimulation in cardiomyocytes subjected
to doxorubicin action [11]. Idarubicin is an antracycline
antibiotic used in the treatment of acute leukaemia and
other malignancies. Amifostine is a well-known cell
protector and, like MEL, involves free radical scaven-
ging. It has been shown that amifostine reduces apop-
tosis and DNA damage in normal (lymphocytes) and
cancer cells (leukaemic K562 and HeLa cells). Melato-
nin protected both cell types against genotoxic effect
and idarubicin-induced apoptosis. The authors conclu-
ded that, despite its recognised potential as an antioxi-
dant, MEL should be administered with caution when
used in combination with cancer chemotherapy agents,
especially in leukaemias [12]. Additionally, the cytosta-
tic effectiveness of daunorubicin was examined, when
applied in parallel with MEL in rats with transplanted
Morris hepatoma [13]. On the one hand, MEL protects
cardiomyocytes by decreasing the intensity of dauno-
rubicin-induced apoptosis but, on the other, it weakens
the cytostatic activity of this drug, as demonstrated by
less frequent necrosis and apoptosis in transplantable
Morris hepatoma cells.
Glutathione peroxidase (GSH-Px) is one of the most
important antioxidative enzymes. In some studies ad-
riamycin (ADR) has been reported to have decreased
the activity of this enzyme in the heart, and MEL did
not restore the decreased activity [6], while in other re-
ports ADR has been described as having no effect [11].
There have been some data to indicate that the effect of
ADR can be dose- and time-dependent [6, 11, 14].
The aim of the study was to examine the effect of
MEL on serum and erythrocyte GSH-Px activity in nor-
mal and pinealectomised rats after ADR.
Material and methods
Doxorubicin was donated by the Pfizer Company (Po-
land). Melatonin and other chemicals were purchased
from Sigma. The experiment was performed in confor-
mity with the principles of the Łódź Local Bioethics Com-
mission for Experiments on Animals (L/BD/196/2004).
Male Wistar rats were used and these weighed ap-
proximately 200 g each at the onset of the study. There
were 8 animals per cage and they were housed in a tem-
perature-controlled and light-controlled room (the li-
ght was turned on at 6.0 a.m. and turned off at 6.0 p.m.)
and had free access to food and water.
The groups of rats remained on a standard diet (Mo-
tycz, Poland) and water with ad libitum access to both.
The Wistar rats were divided into the following three
groups: control animals (Intact), sham-operated (Sham-
Px), and pinealectomised (Px). Each group was divided
into 4 subgroups, which were injected as follows:
1 — saline, 2 — MEL, 3 — ADR and 4 — ADR + MEL.
Pinealectomy was performed by the method of Ku-
szak and Rodin, a well-known model of endogenous
deficiency of melatonin production [15, 16]. Adriamy-
cin was administered 2 months after Px as a single dose
(15 mg/kg, i.p.) 1 hour after the fourth MEL injection.
MEL (5 mg/kg, i.p.) was administered for 4 days before
and 2 days after ADR. After 6 days of treatment the rats
were killed by decapitation.
Blood samples were taken into heparinised micro-
tubes, free of any trace elements. After centrifugation,
plasma was collected and red blood cells (RBC) were
washed in 0.9% NaCl and centrifuged three times. Pla-
sma and RBC samples were stored at –80°C for a maxi-
mum of 2 weeks until biochemical analysis.
The GSH-Px activities of RBC lysate plasma were
assayed by the coupled methods of Paglia and Valenti-
ne with t-butyl hydroperoxide as substrate [17]. The
reaction was carried out at 25°C in a spectrophotome-
ter fitted with a constant-temperature cell housing. The
method was based on the NADPH-coupled reaction,
where oxidised glutathione, produced by GSH-Px and
hydroperoxide, was reduced by exogenous glutathio-
ne reductase and NADPH. Enzymatic activities were
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expressed as units (U) per gram of haemoglobin or units
per ml of plasma. One unit of enzyme was defined as
1 mmol NADPH oxidised per minute per g of Hb
(U/gHb) or per ml of plasma (U/ml). The intra-assay co-
efficient of variation for both materials (6–8 analyses)
was below 3%.
The Kruskal-Wallis test was applied to evaluate the
statistical significance of the results.
Results
GSH-Px activity in serum decreased 3 days after a sin-
gle injection of ADR in a dose of 15 mg/kg in Intact,
Sham-Px and Px rats (Fig. 1). MEL, given for 4 days be-
fore, in a dose of 5 mg/kg/day and continued for 2 days
after ADR, did not change the activity of the enzyme.
Pinealectomy decreased the activity of the enzyme in
all the groups of animals examined (Fig. 2).
In erythrocytes GSH-Px activity decreased only after
ADR in the Px animals (Fig. 3). This effect was not obse-
rved either in the Intact or in the  Sham-Px rats. MEL
Figure 1. Glutathione peroxidase activity in serum (GSH-Px —
U/mL) of rats in three examined groups [Intact, sham-pinealectomised
(Sham-Px) and pinealectomised (Px)] after a single injection of
adriamycin (ADR 15 mg/kg), melatonin (MEL 5 mg/kg) given for 4
days before and 2 days after ADR, or both of them administered together.
The data represent means ± SEM. Level of significance: **p <
< 0.005; ***p < 0.05 vs. controls; ^p < 0.001; ^^p < 0.005
vs. MEL group
Rycina 1. Aktywność peroksydazy glutationu w surowicy (GSP–
Px – U/ml) u szczurów w każdej z trzech badanych grup [nietknięte
(Intact), po operacji pozornej (Sham-Px) i po usunięciu szyszynki
(Px)] po podaniu pojedynczej iniekcji adriamycyny (ADR 15 mg/kg),
melatoniny (MEL 5 mg/kg) podawanej przez 4 dni przed i 2 dni  po
iniekcji ADR lub też podawanej razem z ADR
Dane zaprezentowano w postaci: średnia ± standardowy błąd
pomiaru (SEM, standard error of measure). Poziom istotności:
**p < 0,005; ***p < 0,05 vs. kontrola; ^p < 0,001; ^^p <
< 0,005 vs. grupa MEL
did not change GSH-Px activity after ADR in any of the
groups examined (Fig. 3). The effect of pinealectomy
on the activity of GSH-Px in erythrocytes was not as
strongly expressed as that of serum GSH-Px (Fig. 4).
Discussion
The antioxidative properties of MEL have already been
demonstrated over a period of more than 15 years
[18–20]. The results of previous studies have shown
a protective effect of MEL against oxidative stress, as
induced by many xenobiotics or carcinogens, such as
lipopolysaccharide, hydrogen peroxide, iron, iodide,
thyrotoxicosis, potassium bromate, delta-aminolevulinic
acid, cadmium and liver ischaemia-reperfusion [21–33].
It has been suggested that MEL influences the cardio-
vascular system [2, 3]. It was shown in one of the initial
studies that MEL protected against arrhythmia indu-
ced by ischaemia-reperfusion in isolated rat hearts, well-
known as a model of the induction of free radicals [34].
Sahna et al. [35] suggested that MEL in physiological
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concentrations is important in reducing ischaemia-re-
perfusion arrhythmias, myocyte damage and mortali-
ty, while pharmacological concentrations of this hor-
mone do not increase its beneficial effect. In order to
examine the role of physiological concentrations of pi-
neal indoleamine, the animals were kept in constant li-
ght conditions [36]. It was shown in a subsequent stu-
dy [37] that MEL administration exerted a mitigating
effect on infarct extension. As suggested by Castagnino
et al. [38], a significant cytoprotective effect of MEL is
especially demonstrable in the early phases of myocar-
dial infarction in rats.
Melatonina also suppresses iron-induced lipid pe-
roxidation in many tissues, including the heart [39].
Arteaga et al. [40] compared the antioxidative ef-
fect of a few antioxidants in protecting against the
oxidation of LDL-cholesterol from postmenopau-
sal women. They showed that the antioxidant po-
tency of oestradiol in vitro was 10–100 times higher
than that of either a- and g-tocopherol or of MEL. Be-
not et al. [41] suggest that the antioxidative mecha-
nism of MEL also plays a very important role in blo-
od pressure reduction and in protection against
atherosclerosis.
Figure 2. The effect of pinealectomy on glutathione peroxidase activity in serum (GSH-Px — U/mL) after a single injection of adriamycin
(ADR 15 mg/kg), melatonin (MEL 5 mg/kg) given for 4 days before and 2 days after ADR, or both of them administered together.
The data represent means ± SEM. Level of significance:***p<0.05 vs. controls; ^^p < 0.05 vs. MEL group
Rycina 2. Wpływ usunięcia szyszynki na aktywność peroksydazy glutationu w surowicy (GSP–Px — U/ml) po podaniu pojedynczej
iniekcji adriamycyny (ADR 15 mg/kg), melatoniny (MEL 5 mg/kg) podawanej przez 4 dni przed i 2 dni po iniekcji ADR lub też
podawanej razem z ADR
Dane zaprezentowano w postaci: średnia ± standardowy błąd pomiaru (SEM, standard error of measure). Poziom istotności:
***p < 0,05 vs. kontrola; ^^p < 0,05 vs. grupa MEL
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Figure 3. Glutathione peroxidase activity in erythrocytes (GSH-
Px — U/gHb) of rats in three examined groups [Intact, sham-
pinealectomised (Sham-Px) and pinealectomised (Px)] after a single
injection of adriamycin (ADR 15 mg/kg), melatonin (MEL 5 mg/kg)
given for 4 days before and 2 days after ADR, or both of them
administered together.
The data represent means ± SEM. Level of significance:*p<0.005;
**p < 0.05 vs. controls; ^ p<0.005; ^ ^p < 0.05 vs. MEL group
Rycina 3. Aktywność peroksydazy glutationu w erytrocytach
(GSP–Px — U/gHb) u szczurów w każdej z trzech badanych grup
[nietkniete (Intact), po operacji pozornej (Sham-Px) i po usunięciu
szyszynki (Px)] po podaniu pojedynczej iniekcji adriamycyny (ADR
15 mg/kg), melatoniny (MEL 5 mg/kg) podawanej przez 4 dni przed
i 2 dni po iniekcji ADR lub też podawanej razem z ADR
Dane zaprezentowano w postaci: średnia ± standardowy błąd
pomiaru (SEM, standard error of measure). Poziom istotności:
*p < 0,005; **p < 0,05 vs. kontrola; ^p < 0,005; ^^p < 0,05
vs. Grupa MEL
In our study ADR was used, its cardiotoxicity being
a well-known feature. The mechanism of heart dama-
ge by ADR is complex, but oxidative stress is one of the
most important effects [1]. Pinealectomy was done in
order to examine the effect of MEL at physiological con-
centrations on one group of animals [15, 16].
As suggested by others, the effect of ADR could be
dose- and time-dependent [6, 11, 14]. Li et al. [42] me-
asured myocardial antioxidative enzyme activities,
GSH-Px abundance and protein levels at 1, 2, 4 and
24 h after an ADR single injection at a dose of 2.5 mg/kg
B.W. They found that, while manganese superoxide
dismutase (MnSOD), GSH-Px and catalase activities
were not significantly changed, copper-zinc superoxi-
de dismutase (CuZnSOD) activity was reduced at all
the time points. In earlier studies ADR, in a dose of 13.5
mg/kg B.W. in rabbits, decreased GSH-Px activity in the
heart [43]. While a single dose of ADR (15 mg/kg) resul-
ted in a 56% decrease in cardiac GSH-Px activity, 24 h
after injection in mice, a lesser decrease was noted with
10 mg/kg and no changes at all were observed after
5 mg/kg [44].
In our experiment GSH-Px activity in serum decre-
ased 3 days after the single injection of ADR at a dose
of 15 mg/kg in Intact, Sham-Px and Px rats. MEL, given
for 4 days before ADR administration, in a dose of
5 mg/kg/day and continued for 2 days after ADR, did
not change the activity of the enzyme. Pinealectomy
decreased the activity of serum GSH-Px activity in all
the groups of animals examined, which suggests that
endogenous MEL production deficiency can inhibit the
activity of this enzyme.
In erythrocytes GSH-Px decreased only after ADR
in the Px animals. This effect was not observed either in
the Intact or in the Sham-Px rats. Melatonin did not
change GSH-Px activity after ADR in any of the groups
examined. The effect of Px on the activity of GSH-Px
was not as strongly expressed as that of serum GSH-Px
activity. This reaction could have depended on the half-
life of erythrocytes, which is about 120 days.
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Figure 4. The effect of pinealectomy on glutathione peroxidase activity in erythrocytes (GSH-Px — U/g Hb) after a single injection of
adriamycin (ADR 15 mg/kg), melatonin (MEL 5 mg/kg) given for 4 days before and 2 days after ADR, or both of them administered
together.
The data represent means ± SEM. Level of significance:*p < 0.001; **p < 0.05 vs. controls; ^p<0.001 vs. MEL group
Rycina 4. Efekt usunięcia szyszynki na aktywność peroksydazy glutationu w surowicy (GSP-Px — U/g Hb) po podaniu pojedynczej
iniekcji adriamycyny (ADR 15 mg/kg), melatoniny (MEL 5 mg/kg) podawanej przez 4 dni przed i 2 dni po iniekcji ADR lub też
podawanej razem z ADR
Dane zaprezentowano w postaci: średnia ± standardowy błąd pomiaru (SEM, standard error of measure). Poziom istotności:
*p < 0,001; **p < 0,05 vs. kontrola; ^p < 0,001 vs. grupa MEL
Conclusion
Melatonin, administered in pharmacological concentra-
tions, did not influence serum or erythrocyte glutathio-
ne peroxidase activity, either in normal or in pinealec-
tomised rats after adriamycin. The deficiency of endo-
genous melatonin production may inhibit serum glu-
tathione peroxidase activity.
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